申请人:STC, UNM
公开号:US20170010272A1
公开(公告)日:2017-01-12
In one embodiment, the invention provides methods of identifying the sensitivity and resistance to therapeutic drug regimens in a subject who suffers from, or who is suspected of suffering from, a
Mycobacterium
infection, the method comprising administering (1) isotopically labeled Pretomanid and/or Delaminid, or (2) isotopically labeled ethionamide and/or prothionamide, or (3) isotopically labeled pyrazinamide, or (4) isotopically-labeled isoniazid to the subject and thereafter measuring levels in a subject-derived sample of one or more isotopically-labeled markers corresponding to
Mycobacterium
-actiwated drug metabolites or degradation products, wherein the absence of detectable levels of
Mycobacterium
-activated drug metabolites or degradation products indicates either that the subject does not suffer from a
Mycobacterium
infection or suffers from a
Mycobacterium
infection which is resistant to treatment with the administered drug regimen.